T. Rowe Price Investment Management Reports 16.8% Stake in Apogee Therapeutics Inc.

On April 8, 2026, T. Rowe Price Investment Management, Inc. filed a Schedule 13G/A with the SEC, reporting a significant increase in its stake in Apogee Therapeutics, Inc. (APGE). The investment adviser now beneficially owns 10,291,220 shares of common stock, representing a 16.8% ownership interest in the company. This is a substantial increase from the previously reported 0.0% position. Of the total shares held, the filer possesses sole voting power over 9,762,311 shares and sole dispositive power over the full 10,291,220 shares. The filing highlights that the T. Rowe Price Capital Appreciation Fund specifically holds 5,295,932 shares, accounting for 9.7% of the class. The securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. T. Rowe Price Investment Management, Inc. is a Maryland-based investment adviser and explicitly denies beneficial ownership of these securities beyond its advisory capacity.